Recurrent thymic carcinoma treated with anterior median thoracotomy,
innominate vein replacement for superior vena cava, and iodide
implantation: A case report and review of the literature
- zhong zheng Chen,
- Wen-dong Qu,
- Xingshu zhang,
- Yongxiang Song
zhong zheng Chen
Affiliated Hospital of Zunyi Medical University
Author ProfileWen-dong Qu
Affiliated Hospital of Zunyi Medical University
Author ProfileXingshu zhang
Affiliated Hospital of Zunyi Medical University
Author ProfileAbstract
Thymic neuroendocrine tumors are rare malignant tumors with
neuroendocrine functions located in the anterior mediastinum thymic
region. They exhibit a high degree of malignancy and can early invade
surrounding fat,pericardium, pleura, major blood vessels, and
lungs,posing a significant risk of recurrence.Here, we report a case of
recurrent thymic cancer treated with complete surgical resection,
replacement of the innominate vein, superior vena cava formation, and
iodine ion insertion.A 51-year-old male diagnosed with stage lllA
malignant thymoma in November 2021, accompanied by lymph node
metastasis,involving the peripheral left lung.The patient underwent six
cycles of adjuvant immunotherapy with pembrolizumab and cisplatin plus
etoposide, along with one course of radiotherapy
postoperatively.Subsequently, the patient received regular immunotherapy
and follow-up at our hospital. In October 2023,chest CT revealed tumor
recurrence, with infiltration into the pericardium, bilateral innominate
veins, superior vena cava, and brachiocephalic artery.Subsequently, the
patient underwent a midline thoracotomy for extensive resection of
recurrent thymic tumor,enlargement of pericardial resection, left
innominate vein-to-right atrial artificial grafting,superior vena cava
formation,and iodine-125radioisotope brachytherapy.Aggressive surgical
intervention combined with adjuvant therapy is an essential treatment
modality for locally advanced thymic cancer involving the superior vena
cava and surrounding blood vessels.04 Apr 2024Submitted to Cancer Reports 05 Apr 2024Submission Checks Completed
05 Apr 2024Assigned to Editor
05 Apr 2024Review(s) Completed, Editorial Evaluation Pending
11 Apr 2024Reviewer(s) Assigned
19 Jul 2024Editorial Decision: Revise Major
15 Aug 20241st Revision Received
16 Sep 2024Submission Checks Completed
16 Sep 2024Assigned to Editor
16 Sep 2024Review(s) Completed, Editorial Evaluation Pending
25 Oct 2024Reviewer(s) Assigned